Literature DB >> 25905517

Development of the Plutonium-DTPA Biokinetic Model.

Kevin Konzen1, Richard Brey.   

Abstract

Estimating radionuclide intakes from bioassays following chelation treatment presents a challenge to the dosimetrist due to the observed excretion enhancement of the particular radionuclide of concern where no standard biokinetic model exists. This document provides a Pu-DTPA biokinetic model that may be used for making such determination for plutonium intakes. The Pu-DTPA biokinetic model is intended to supplement the standard recommended biokinetic models. The model was used to evaluate several chelation strategies that resulted in providing recommendations for effective treatment. These recommendations supported early treatment for soluble particle inhalations and an initial 3-day series of DTPA treatments for wounds. Several late chelation strategies were also compared where reduced treatment frequencies proved to be as effective as multiple treatments. The Pu-DTPA biokinetic model can be used to assist in estimating initial intakes of transuranic radionuclides and for studying the effects of different treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25905517     DOI: 10.1097/HP.0000000000000283

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  2 in total

1.  The Incorporation of Radionuclides After Wounding by a "Dirty Bomb": The Impact of Time for Decorporation Efficacy and a Model for Cases of Disseminated Fragmentation Wounds.

Authors:  Alexis Rump; Daniela Stricklin; Andreas Lamkowski; Stefan Eder; Michael Abend; Matthias Port
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-01-01       Impact factor: 4.730

2.  From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents.

Authors:  Dahlia D An; Birgitta Kullgren; Erin E Jarvis; Rebecca J Abergel
Journal:  Chem Biol Interact       Date:  2016-03-31       Impact factor: 5.192

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.